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Abstract
Background: Cystine-knot miniproteins, also known as knottins, have shown great potential as molecular scaffolds for the
development of targeted therapeutics and diagnostic agents. For this purpose, previous protein engineering efforts have
focused on knottins based on the Ecballium elaterium trypsin inhibitor (EETI) from squash seeds, the Agouti-related protein
(AgRP) neuropeptide from mammals, or the Kalata B1 uterotonic peptide from plants. Here, we demonstrate that Agatoxin
(AgTx), an ion channel inhibitor found in spider venom, can be used as a molecular scaffold to engineer knottins that bind
with high-affinity to a tumor-associated integrin receptor.
Methodology/Principal Findings: We used a rational loop-grafting approach to engineer AgTx variants that bound to avb3
integrin with affinities in the low nM range. We showed that a disulfide-constrained loop from AgRP, a structurally-related
knottin, can be substituted into AgTx to confer its high affinity binding properties. In parallel, we identified amino acid
mutations required for efficient in vitro folding of engineered integrin-binding AgTx variants. Molecular imaging was used
to evaluate in vivo tumor targeting and biodistribution of an engineered AgTx knottin compared to integrin-binding
knottins based on AgRP and EETI. Knottin peptides were chemically synthesized and conjugated to a near-infrared
fluorescent dye. Integrin-binding AgTx, AgRP, and EETI knottins all generated high tumor imaging contrast in U87MG
glioblastoma xenograft models. Interestingly, EETI-based knottins generated significantly lower non-specific kidney imaging
signals compared to AgTx and AgRP-based knottins.
Conclusions/Significance: In this study, we demonstrate that AgTx, a knottin from spider venom, can be engineered to
bind with high affinity to a tumor-associated receptor target. This work validates AgTx as a viable molecular scaffold for
protein engineering, and further demonstrates the promise of using tumor-targeting knottins as probes for in vivo
molecular imaging.
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Introduction
There is a critical need for in vivo molecular imaging agents that
bind specifically and with high affinity to clinical targets of interest,
while displaying desirable pharmacokinetics and tissue biodistribu-
tion properties [1,2]. For cancer, ideal molecular imaging agents
are ones that exhibit robust tumor localization and rapid clearance
from non-target tissues and organs [3,4]. Such attributes translate
into high imaging contrast at early time points after probe
injection, and low nonspecific or background imaging signals that
otherwise obscure accurate identification of malignant tissue.
Recently, cystine-knot miniproteins, known as knottins, have
emerged as promising agents for non-invasive molecular imaging
of tumors in living subjects [5–7]. Knottins share a common
disulfide-bonded framework, and contain loops of variable length
and composition that are constrained to a core of anti-parallel
beta-strands (Fig. 1) [8]. This structure confers high thermal,
chemical, and proteolytic stability [9,10], which is desirable for in
vivo biomedical applications. In addition, the small size of knottins
(,30–60 amino acids) affords rapid blood clearance and the
potential for chemical synthesis, allowing facile incorporation of a
variety of imaging moieties [11,12].
Polypeptides containing cystine-knot motifs are found in myriad
organisms such as plants, insects, and mammals, and carry out
diverse functions including protease inhibition, ion channel
blockade, and antimicrobial activity [13,14]. Although naturally-
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occurring knottins have found important clinical applications
[15,16], protein engineering is playing an increasing role in
creating knottins that possess novel molecular recognition prop-
erties for use as therapeutics and diagnostics [17–20]. The
disulfide-constrained loop regions of native knottins tolerate high
levels of sequence diversity (Fig. 1B), providing a robust molecular
framework for engineering proteins that recognize a variety of
biomedical targets. Despite the large number of natural proteins
with cystine knot motifs, engineering efforts have mainly utilized
three knottins as molecular scaffolds: the Ecballium elaterium trypsin
inhibitor-II (EETI), which is found in the seeds of the squirting
cucumber [21,22]; a truncated version of the Agouti-related
protein (AgRP), a neuropeptide that is involved in regulating
metabolism and appetite [23,24]; and the cyclotide Kalata B1
from the African plant Oldenlandia, which has uterotonic activities
[25].
We previously used yeast-surface display and high-throughput
library screening to identify knottin variants, based on EETI and
AgRP, that possess high affinity and specificity for integrin
receptors expressed on tumor cells and their neovasculature
(Fig. 1) [26,27]. Engineered integrin-binding EETI and AgRP
knottins were labeled with a variety of contrast agents and used to
non-invasively image tumors across multiple modalities, including
positron emission tomography (PET) [28–34], single-photon
emission computed tomography (SPECT) [35], ultrasound [36],
and optical imaging [30,31]. In these studies, engineered EETI
and AgRP knottins exhibited rapid tumor localization and blood
clearance via the kidneys, resulting in robust tumor contrast
compared to the surrounding tissue [28–34]. Given the critical
roles that integrins play in tumor cell survival, invasion, metastasis,
and angiogenesis [37–40], molecular imaging agents that selec-
tively target tumor-associated integrins have potential diagnostic
Figure 1. AgTx, AgRP, and EETI knottins engineered to bind tumor-associated integrins. (A) Native knottin structures. AgTx IVB (PDB
1OMB), truncated AgRP (PDB 1MR0), and EETI-II (PDB 2ETI), with disulfide bonds shown in gold, and native loops that were mutated to bind tumor-
associated integrins shown in red. Structures were rendered in PyMOL. (B) Schematic of protein engineering strategy and sequences of native and
engineered knottins used in this study. Conserved cysteine residues are shown in gold, and bars indicate disulfide bond connectivity. The N- and C-
termini of AgTx were truncated and the sequences of isoforms IVA and IVB were combined to create a knottin scaffold with no lysine residues (cyan),
allowing for site-specific conjugation of AF680 at the N-terminal amino group. The integrin-binding loop from AgRP 7C was grafted into the
structurally analogous loop of this new scaffold to create AgTx 7C. Mutated loops are underlined and shown in red. * indicates knottins used for in
vivo imaging. EETI RDG contains a scrambled sequence that does not bind integrins, and was used as a negative control.
doi:10.1371/journal.pone.0060498.g001
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applications in disease staging and management, and monitoring
response to therapy [41,42].
Spider venoms are a rich source of diverse peptides containing a
cystine knot motif [43,44]. Here, we demonstrate the first use of
Agatoxin (AgTx), a venom-derived knottin [45,46], as a molecular
scaffold for protein engineering. AgRP, which is derived from
mammals, is structurally homologous to AgTx, despite the fact
that their sequences share only one identical residue beyond their
conserved cysteines (Fig. 1). Using a rational approach, we grafted
the integrin-binding loop from an engineered AgRP mutant into
an AgTx scaffold, resulting in an AgTx variant that bound to
tumor cells with low nanomolar affinity. Through this work, we
identified scaffold mutations required for efficient in vitro folding
of this engineered AgTx variant. We showed that engineered
integrin-binding knottins based on AgTx, AgRP, and EETI can be
conjugated to a near-infrared fluorescent dye and used for in vivo
optical imaging of tumors in mice, but that EETI-based knottins
had lower non-specific accumulation in the kidneys. This work
validates AgTx as a molecular scaffold for protein engineering and
in vivo imaging applications, expanding the repertoire of knottins
that can be developed as potential therapeutic and diagnostic
agents.
Results
Engineering a truncated AgTx scaffold that binds avb3
integrin
EETI 2.5F is an engineered knottin that binds to avb3, avb5,
and a5b1 integrins [26], while AgRP 7C is an engineered knottin
that binds only to avb3 integrin [27]. To develop AgTx as a
scaffold for molecular engineering, we first reduced its size to
minimize complexity and allow for more facile peptide synthesis.
There are two primary natural isoforms, AgTx IVA and IVB,
which possess 71% sequence homology [45]. These isoforms each
contain 48 amino acids, including disordered N- and C-terminal
regions [46]. We defined the knottin core of AgTx IVA and IVB
by sequence comparison with a truncated AgRP fragment [24]
that was previously used as a scaffold to engineer integrin-binding
knottins [27]. As the C-terminal region of AgTx is proposed to
mediate ion channel binding and inhibition [46], we removed it to
mitigate potential toxicity concerns of using full-length AgTx for in
vivo studies. N- and C-terminal truncations resulted in peptides
containing 35 amino acids for each AgTx isoform (Fig. 1B). AgTx
IVA and IVB contain 3 and 2 lysine residues, respectively, at
different positions throughout the polypeptide chain. We com-
bined the sequences of the AgTx IVA and IVB isoforms to
eliminate all lysine residues, so that a molecular imaging probe
could be selectively conjugated to the N-terminal amino group.
We define this combined sequence as ‘‘AgTx, no lysines’’ (Fig. 1B).
To engineer this new AgTx scaffold to bind integrins we relied on
the overall structural similarity between AgTx and AgRP (Fig. 1A),
and substituted the integrin-binding loop from a previously
engineered knottin variant, AgRP 7C, into the analogous location
within AgTx to produce AgTx 7C (Fig. 1B).
A specific arginine deletion in the integrin-binding AgTx
variant promoted efficient in vitro folding
The linear precursor of the integrin-binding knottin AgTx 7C
was chemically synthesized using solid-phase peptide synthesis.
Crude peptide was folded in vitro using conditions previously
established for disulfide bond formation with AgRP 7C [19], and
the folded peptide was purified by reversed-phase high-perfor-
mance liquid chromatography (RP-HPLC). Analytical-scale RP-
HPLC was used to compare the crude peptide, folding reaction,
and purified knottin (Fig. 2). Analysis of the folding reaction
indicated the presence of a sharp elution peak (Fig. 2B), which is
characteristic of folded knottin that can be separated from
misfolded isomers. However, the molecular mass of this species
was 156 Da less than expected, suggesting the deletion of an
arginine residue (Fig. 2D). Upon further analysis, a peptide of the
expected molecular mass was indeed present in the crude product
of the synthesis (Fig. 2A), but efficient folding was only observed
Figure 2. Synthesis and folding of AgTx 7C indicated a deletion product. (A–C) RP-HPLC chromatograms. (A) The crude peptide from solid-
phase peptide synthesis had two major peaks, one with the expected mass and the other with a loss of 156 Da, indicating possible deletion of an
arginine residue. (B) Folding of crude peptide yielded a sharp peak which was 156 Da less than the expected mass. (C) Purified, folded peptide
exhibited a single, sharp peak. (D) Expected and observed masses of indicated HPLC peaks as analyzed by MALDI-TOF mass spectrometry. Note that
there is an 8 Da difference between unfolded and folded AgTx 7C due to the formation of 4 disulfide bonds.
doi:10.1371/journal.pone.0060498.g002
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for the AgTx 7C deletion variant. This serendipitous finding
prompted us to determine the identity of this AgTx 7C deletion.
Enzymatic digestion and tandem mass spectrometry analysis
indicated the absence of an arginine at position 21 (Fig. S1). In
solid-phase peptide synthesis, coupling of an arginine residue is
sometimes problematic [47,48]. The side chain of arginine has two
reactive nitrogen groups, and although one nitrogen is protected
by 2,2,4,6,7-pentametyldihydrobenzofuran-5-sulfonyl (Pbf) during
the synthesis, the unprotected nitrogen can form temporary
intramolecular bonds, reducing coupling efficiency. The coupling
efficiency is also reduced by the conformational rigidity of proline,
whose unique side chain forms a covalent bond with the backbone
of the growing peptide chain. Thus, the coupling of P22 followed
by R21 would be expected to proceed at particularly low
efficiency, potentially explaining the presence of high amounts of
the AgTx 7C deletion product observed in our synthesis. To
confirm these results, AgTx 7C was chemically synthesized
without an arginine residue at position 21 (AgTx 7C DR21),
resulting in a single species with the expected mass for both the
purified linear precursor and the folded product (Fig. S2A, B). As
further evidence that R21 was the problematic arginine residue for
coupling, an AgTx variant was synthesized with an arginine
deletion at position 9 (AgTx 7C DR9). The resulting peptide was
again a mixture of two species, one with the correct mass, and one
with a mass of 156 Da less than expected, presumably containing
the additional R21 deletion from inefficient coupling. However, in
this case we found that both AgTx peptides folded efficiently (data
not shown). The cysteine adjacent to R9 forms a disulfide bond
with the cysteine adjacent to P22, suggesting that the R9 deletion
promotes folding through reduced steric constraints or reduced
charge repulsion.
Additional scaffold mutations promote efficient folding
of AgTx 7C
To determine if other modifications to the AgTx scaffold
influence folding, we synthesized additional AgTx 7C variants
based on sequence variations of the AgTx isoforms. The R21
deletion is located in a region where the sequences of AgTx IVA
and IVB differed. The ‘‘lysine-free’’ AgTx scaffold we defined
included residues P22 and R24 from AgTx IVB (Fig. 1B); the
corresponding residues in AgTx IVA are G22 and I24. A
comparison of the AgTx IVA and AgTx IVB structures using
the TM-align server [49] reveals that while overall the two
structures are similar (TM-score of 0.70 and RMSD of 1.40), the
region containing residues 22 and 24 has the largest variation
compared to the rest of the structure. The inclusion of P22 in our
combined AgTx scaffold, which directly precedes R21, might limit
conformational flexibility required for efficient polypeptide fold-
ing, particularly when the 9-amino acid integrin-binding loop was
incorporated into the construct. To test this hypothesis, we
substituted G22 and I24 from AgTx IVA into the knottin scaffold,
resulting in a variant denoted AgTx 7C P22G R24I. The
mutations P22G and R24I resulted in efficient folding of AgTx
7C (Fig. S2). Moreover, only a single peptide species was produced
from these syntheses, indicating that the substitution of proline
with glycine at position 22 allows efficient coupling of the R21
residue. Finally, an AgTx variant incorporating P22G and R24I
mutations and the DR21 deletion (denoted AgTx 7C DR21 P22G
R24I) also demonstrated efficient folding (Fig S2). Folding
conditions for each AgTx variant are described in the Supple-
mental Methods. Collectively, these results demonstrate that
amino acid substitutions and deletions within the knottin scaffold
can influence or promote more efficient folding.
Engineered AgTx variants bind avb3 integrin with high
affinity
Competition binding assays were used to measure the relative
affinities of the AgTx 7C variants and AgRP 7C to K562 leukemia
cells transfected to express high levels of avb3 integrin [50].
Recombinant FLAG-AgRP 7A, a related engineered knottin that
binds specifically to avb3 integrin with high affinity [27], was used
as the competitor. FLAG-AgRP 7A contains an N-terminal FLAG
epitope tag (DYKDDDDK), which allows detection of cell surface
binding by flow cytometry using a fluorescently labeled anti-FLAG
antibody. All AgTx 7C variants showed similar relative binding
affinities to K562-avb3 cells with half-maximal inhibitory concen-
tration (IC50) values in the single-digit nanomolar range (Fig. 3).
AgRP 7C and AgTx 7C DR21 had nearly identical IC50 values of
2.261.0 nM and 2.360.5 nM, respectively, confirming that loop
grafting of a binding epitope from AgRP to the structurally similar
AgTx scaffold was a successful protein engineering strategy. As the
conformation of the Arg-Gly-Asp (RGD) integrin-binding motif is
critically important for mediating high-affinity interactions
[51,52], these results suggest that AgTx scaffold mutations at
positions 9, 21, 22, or 24 do not significantly affect overall protein
structure.
Knottin peptides conjugated to AF680 dye retain high
affinity integrin binding
For simplicity, we chose to move forward with AgTx 7C DR21
for in vivo molecular imaging studies. To visualize tumor targeting
and tissue biodistribution, we conjugated the near-infrared dye
Figure 3. Engineered AgTx 7C variants bind to K562-avb3 cells with similar IC50 values. Varying concentrations of AgRP 7C and AgTx 7C
variants were incubated with FLAG-AgRP 7A and allowed to compete for binding to integrin receptors expressed on the surface of K562-avb3 cells.
Representative competition binding curves are shown, and are plotted as knottin concentration versus the fraction of FLAG-AgRP 7A bound. IC50
values reported as mean of three experiments 6 SD.
doi:10.1371/journal.pone.0060498.g003
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Alexa Fluor 680 (AF680) to the N-terminal amino group of AgTx
7C DR21 (Fig. S3A). We also synthesized AF680-labeled versions
of AgRP 7C and EETI 2.5F for comparison studies. AF680-
labeled EETI RDG, which contains a scrambled integrin
recognition sequence [26,30], served as a non-binding control.
AF680-labeled knottin peptides were purified by RP-HPLC and
had the expected masses for the addition of one dye molecule (Fig.
S3B, C). Competition binding assays were used to determine if
AF680 conjugation affected integrin recognition. FLAG-AgRP 7A
was used to compete for knottin binding to U87MG human
glioblastoma cells (Fig. 4). Unlabeled knottins and AF680-labeled
knottins had similar IC50 values in the low nanomolar range for
each peptide tested, confirming that dye conjugation did not
interfere with high-affinity integrin binding (Table 1).
Integrin-binding knottins exhibit high tumor contrast in
murine xenograft models
AF680-labeled knottins were evaluated as molecular imaging
probes in subcutaneous U87MG tumor xenograft models. Non-
invasive optical imaging was performed over a 24 hr time period
after murine tail vein injection of 1.5 nmol AF680-labeled knottin
peptide (Fig. 5). Whole-body fluorescent imaging signals were
prominent at 1–2 hr post-injection for AgTx 7C DR21, AgRP 7C,
and EETI 2.5F, in contrast to the EETI RDG control, which
mainly showed kidney signal due to renal clearance (Fig. 5A). For
all integrin-binding knottins, tumor signals steadily decreased over
the 24 hr imaging experiment (Fig. 5B). AgTx 7C DR21 and
AgRP 7C generated high kidney imaging signals at early time
points, which decreased over time (Fig. 5C). In contrast,
significantly lower kidney imaging signals were observed in mice
injected with EETI 2.5F and EETI RDG at all time points. EETI
2.5F generated the greatest tumor imaging contrast amongst all
the knottins (Fig. 5D), as defined by the ratio of the tumor signal to
the normal flank tissue of the same mouse. A comparison of AgTx
7C DR21 versus AgRP 7C showed similar tumor contrast
throughout the imaging time course, with levels significantly
higher than the EETI RDG control. Maximum tumor-to-normal
tissue contrast was observed at 6–8 hr post injection after
clearance of probe from non-target tissue, with values of
10.061.1, 6.360.9, and 6.861.1 for EETI 2.5F, AgRP 7C, and
AgTx 7C DR21, respectively (Fig. 5D).
EETI-based knottins generate low kidney imaging signals
compared to AgRP 7C and AgTx 7C DR21
To confirm tissue biodistribution observed with in vivo optical
imaging experiments, mice were sacrificed at 4 hr and ex vivo
imaging was performed on resected organs and tissue, including
the tumor, kidney, liver, muscle, and blood (Fig. 6). Ex vivo
imaging verified tumor-specific signals observed in mice injected
with AF680-labeled AgTx 7C DR21, AgRP 7C, and EETI 2.5F
Figure 4. Unlabeled and AF680-labeled knottins bind U87MG cells with high affinity. Unlabeled (open squares, dashed line) and AF680-
labeled (closed circles, solid line) knottins similarly compete off FLAG-AgRP 7A knottin binding to avb3 integrins expressed on U87MG glioblastoma
cells. Representative competition binding curves shown for (A) AgTx 7C DR21, (B) AgRP 7C, (C) EETI 2.5F, and (D) EETI RDG control. IC50 values
reported as mean of three experiments 6 SD.
doi:10.1371/journal.pone.0060498.g004
Table 1. Relative binding affinities of unlabeled and AF680-
labeled knottins on U87MG cells, reported as IC50 values.
IC50 (nM)
Knottin Unlabeled AF680 labeled
AgTx 7C DR21 1061 1163
AgRP 7C 4.060.4 9.260.2
EETI 2.5F 2.460.1 4.060.2
EETI RDG (-) (-)
(-) = no competition observed at highest concentration tested. IC50 values
reported as mean of three experiments 6 SD.
doi:10.1371/journal.pone.0060498.t001
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compared to the EETI RDG control. In agreement with non-
invasive in vivo optical imaging experiments, EETI 2.5F and
EETI RDG generated low kidney signals at 4 hr post injection
compared to AgTx 7C DR21 and AgRP 7C. In all animals,
fluorescent signal was negligible in the muscle, blood, and liver,
confirming efficient clearance from these organs and tissue.
Discussion
Previous protein engineering studies have focused on the
development and application of knottin scaffolds based on EETI,
AgRP, and Kalata B1 [5–7,17,18,28]. Our current work expands
the examples of knottins validated as molecular scaffolds to include
AgTx. We first truncated the N- and C-termini of AgTx IVB to
simplify the scaffold and abolish its native function. Based on
structural similarities between AgRP and AgTx knottins, we next
grafted a disulfide-bonded integrin-binding loop from an engi-
neered AgRP variant into AgTx, and showed that high-affinity
integrin binding was conferred with this new construct. A similar
approach could potentially be used to incorporate disulfide-
bonded cyclic peptides, such as those identified from phage display
libraries [53], into knottin scaffolds.
Through this work, we identified an arginine deletion (DR21)
that was required for efficient folding of the integrin-binding
variant AgTx 7C. In contrast, native AgTx did not require this
DR21 mutation for efficient folding (data not shown). The
engineered integrin-binding loop we introduced into AgTx 7C is
9 amino acids in length, while the corresponding loop in native
AgTx consists of 6 amino acids. This longer loop, together with the
Figure 5. Non-invasive in vivo imaging of AF680-labeled knottins in U87MG tumor xenografts. (A) Representative whole-body
fluorescent images of murine U87MG tumor xenografts injected via tail vein with 1.5 nmol AF680-labeled knottins AgTx 7C DR21, AgRP 7C, EETI 2.5F,
and EETI RDG control. Tumors (white arrow) and kidneys (K) are indicated. Radiant efficiency [ = ] (p/s/cm2/sr)/(mW/cm2). (B–C) Quantification of
imaging signals, reported as the total radiant efficiency, in the (B) tumor and (C) kidney over 24 hr. Total radiant efficiency [ = ] (p/s)/(mW/cm2). (D)
Imaging contrast, reported as the ratio of fluorescent signals for tumor versus normal tissue. There is no statistical difference in imaging contrast
between AgTx 7C DR21 and AgRP 7C at all time points measured (p.0.05). Error bars represent 6 SE, n = 4 for all knottins.
doi:10.1371/journal.pone.0060498.g005
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inclusion of P22 which directly precedes the R21 mutation, may
have disrupted an optimal balance of flexibility, size, and charge of
amino acid side chains critical to folding amongst these isoforms.
As a result of these changes, mutations immediately preceding the
engineered integrin-binding loop were required for efficient
folding. The AgTx mutations DR21 and/or P22G and R24I
could potentially restore the thermodynamic favorability of knottin
folding by removing steric clashes, improving backbone flexibility,
or improving interaction of the beta strands in the knottin core. All
of these AgTx 7C variants had similar relative binding affinities
(Fig. 3), demonstrating that the scaffold modifications did not
significantly affect the conformation of the engineered integrin-
binding loop. AgRP 7C demonstrated efficient folding without the
requirement for additional scaffold mutations. In contrast to the
AgTx variants, AgRP has two Cys-Tyr-Cys motifs that flank the
engineered integrin-binding loop. These Tyr residues have been
proposed to participate in interactions that help mediate disulfide
bond formation in native AgRP [54]. In addition, the Arg21 and
Pro22 amino acid residues that were problematic for AgTx folding
are Ala and Thr, respectively, in AgRP, which likely imparts
conformational flexibility that better accommodates the engi-
neered integrin-binding loop.
A myriad of small molecules and peptides containing an RGD
integrin-binding motif have been developed, and several have
advanced to human trials for diagnostic applications [55,56]. We
showed that engineered integrin-binding knottins generate signif-
icantly higher levels of tumor contrast in subcutaneous U87MG
xenograft models compared to imaging probes based on
c(RGDfK) and c(RGDyK), two well-characterized cyclic penta-
peptides that bind to avb3 and avb5 integrins. Maximum tumor-to-
normal tissue contrast ratios for AF680-c(RGDfK) and AF680-
c(RGDyK) were 3.260.5 and 2.860.3, respectively (Fig. S4),
compared to imaging contrast ratios of 6-10 for AF680-labeled
integrin-binding knottins (Fig. 5D). In addition to the potential for
improved tumor contrast, molecular imaging probes can be
directly conjugated to the knottin N-terminus without disrupting
receptor binding interactions. The N-terminus of AgTx 7C DR21
is positioned on the opposite side of the knottin relative to the
integrin-binding loop (Fig. 1). As such, conjugation of a fluorescent
dye molecule to the N-terminus of AgTx 7C DR21 did not
interfere with high affinity binding to cell surface integrin
receptors. Similar results were obtained with imaging probe
conjugation to the N-terminus of AgRP 7C and EETI 2.5F. In
comparison, small molecules and disulfide-constrained cyclic
peptides present binding epitopes within a more limited frame-
work that can sometimes be disrupted upon imaging probe
conjugation [53,55].
Another goal of our study was to compare the in vivo
biodistribution profiles of engineered knottins derived from
different organisms, including spiders, mammals, and plants.
AF680-labeled AgTx 7C DR21, AgRP 7C, and EETI 2.5F all
exhibited high tumor contrast in optical imaging experiments. The
high tumor-to-normal imaging signals observed at early time
points after knottin administration are consistent with theoretical
and experimental studies examining the relationship between
optimal molecular size and affinity needed for effective tumor
targeting [57–60]. In particular, while small proteins accumulate
rapidly in tumors, they must bind their targets with high affinity to
be retained. Together, these results support further development
of low molecular weight, high affinity tumor-targeting agents for
molecular imaging applications.
Integrin-binding knottins based on the EETI scaffold exhibited
remarkably low kidney signals, either due to more rapid clearance
or reduced non-specific kidney accumulation compared to AgTx
7C DR21 and AgRP 7C. These results are consistent with our
previous imaging studies using radiolabeled EETI and AgRP
proteins [28–34]. In comparison, molecular imaging probes based
on antibodies, antibody fragments, and other ‘‘alternative
scaffolds’’ including affibodies, DARPins, and fibronectin do-
mains, all exhibit high imaging signals in the liver and/or kidneys
[57,61–64], which raises toxicity concerns and challenges for
imaging the abdominal and thoracic regions. Such high kidney
signals have been attributed to metabolites that accumulate in the
kidneys through mechanisms such as renal tubular reabsorption
[65,66]. We previously showed that AgRP 7C exhibits higher
levels of metabolic breakdown in the liver, kidneys, and tumor
compared to EETI 2.5F, although both probes were remarkably
stable in serum and blood and were excreted intact in the urine
[29,30].
The amino acid sequences of the knottin peptides could also
play a role in their tissue biodistribution properties. In addition to
Figure 6. Ex vivo imaging of tissue and organs from U87MG
tumor xenografts. (A) Representative ex vivo images of tumor,
kidney, liver, muscle, and blood at 4 hr post injection of 1.5 nmol
AF680-labeled knottins. (B) Quantification of total imaging signal per
organ, normalized to organ mass, corroborates high kidney signals for
AgTx 7C DR21 and AgRP 7C compared to EETI-based knottins. No
fluorescent signal was detectable in blood samples at 4 hr post probe
injection. Error bars represent 6 SE. For all knottins, n = 9, except EETI
RDG (n = 4).
doi:10.1371/journal.pone.0060498.g006
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having different scaffold sequences, the engineered loops of EETI
2.5F (PRPRGDNPPLT) and EETI RDG (VTGRDGSPASS) are
markedly different from that of AgRP/AgTx 7C
(YGRGDNDLR). In agreement with this hypothesis, our
colleagues recently reported that highly charged residues, partic-
ularly arginine and glutamic acid, of Momordica cochinchinensis
trypsin inhibitor-II knottins contribute greatly to non-specific
kidney retention [67]. In addition, an 111In-labeled version of one
of our alternative engineered integrin-binding AgRP knottins
(AgRP 6E, engineered loop sequence: VERGDGNRR) had an
approximately 50% reduction in kidney signal compared to 111In-
labeled AgRP 7C [35], demonstrating the influence of the
engineered loop on tissue biodistribution. Efforts to reduce
undesirable non-target tissue accumulation have included: 1)
introducing mutations that increase hydrophilicity and remove
charged groups, 2) covalently attaching polymers such as
polyethylene glycol, and 3) co-administration of the probe with
charged amino acids or agents that block specific transporter
receptors or alter overall kidney physiology [65,66,68]. The
complexity of potential mechanisms for probe or metabolite
retention in the kidneys highlights the need for polypeptides that
do not require extensive efforts to block renal accumulation. Thus,
in future studies it will be interesting to further explore the
relationship between amino acid sequence, metabolic stability, and
in vivo biodistribution properties of engineered knottins.
The methods we report for chemical synthesis, folding, dye
conjugation, and purification of knottins as molecular imaging
probes are compatible with production of clinical grade material,
although yield has not yet been evaluated in a large-scale (.1
gram) production process. The homogeneity of the final product,
with one fluorophore attached to the N-terminus of each knottin
peptide, is desirable for clinical translation. Knottins are proposed
to be non-immunogenic due to their high stability, which is
thought to preclude presentation of peptide fragments to molecules
that mediate immune function [69]. In addition, smaller quantities
of knottin are used for in vivo molecular imaging compared to
therapeutic dosage levels; however, immunogenicity and toxicity
will need to be evaluated for each compound intended for human
clinical trials.
In summary, we demonstrate that AgTx, an ion channel
inhibitor found in spider venom, can be used as a pliable
framework for constructing peptides that bind with high-affinity to
a clinically-relevant integrin receptor. This work expands the
repertoire of knottins that have been validated as molecular
scaffolds for protein engineering, and provides insights for the




All animal procedures were in compliance with Protocol 22942
approved by the Stanford University Administrative Panels on
Laboratory Animal Care. All procedures were conducted while
animals were under general anesthesia with isofluorane, and all
efforts were made to minimize suffering.
Materials, reagents, and cell lines
Integrin binding buffer (IBB) was composed of 20 mM Tris
(pH 7.5) with 1 mM MgCl2, 1 mM MnCl2, 2 mM CaCl2,
100 mM NaCl, and 1 mg/mL bovine serum albumin (BSA).
BPBS buffer was composed of phosphate-buffered saline (PBS) and
1 mg/mL BSA. 9-fluorenylmethyloxycarbonyl (Fmoc)-protected
amino acids were purchased from Novabiochem/EMD Chemicals
Inc. or CS Bio. The cyclic pentapeptides c(RGDfK) and
c(RGDyK) were purchased from Peptides International. Human
U87MG glioblastoma cells (ATCC) were cultured in DMEM
(Gibco) supplemented with 10% fetal bovine serum (FBS) and 1%
penicillin-streptomycin (Gibco). K562 cells transfected with avb3
integrins (courtesy of S. Blystone) were cultured in IMDM (Gibco)
supplemented with 1 mg/ml active geneticin (Gibco), 10% FBS,
and 1% penicillin-streptomycin [50].
Peptide synthesis, folding, and purification
Knottin peptides were prepared as previously described in detail
[19]. Briefly, linear precursor peptides were synthesized on a CS
Bio CS336 instrument using Fmoc-based solid-phase peptide
synthesis. After side-chain deprotection and resin cleavage,
peptides were folded by promoting disulfide bond formation in
oxidation buffers optimized for each peptide (Text S1). Folded
knottins were purified by preparative-scale RP-HPLC using a
Varian Prostar instrument and Vydac C18 columns, where each
folded peptide eluted as a sharp peak with an altered retention
time from unfolded or misfolded precursors. Linear gradients of
90% acetonitrile in water containing 0.1% (v/v) trifluoroacetic
acid were used for all peptide purifications, which were monitored
at absorbances of 220 nm and 280 nm. Peptide purity was
analyzed by analytical-scale RP-HPLC using a Vydac C18 column.
Molecular masses were determined by matrix-assisted laser
desorption/ionization time-of-flight mass spectrometry (MALDI-
TOF-MS; Stanford Protein and Nucleic Acid Facility) or
electrospray ionization mass spectrometry (ESI-MS; Stanford
Vincent Coates Foundation Mass Spectrometry Laboratory).
Following purification, folded knottins were lyophilized and stored
at room temperature until used. Purified knottins were dissolved in
PBS, and concentrations were determined by amino acid analysis
(UC Davis Proteomics Core Facility).
AF680 dye conjugation
Pure, folded knottin (2 mg/ml) was incubated for 1 hr at room
temperature and then at 4 uC overnight (with stirring) with Alexa
Fluor 680 carboxylic acid, succinimidyl ester (Invitrogen) in a
0.1 M sodium bicarbonate solution, pH 8.0 at a 5:1 dye/peptide
molar ratio (Fig. S3A). The resulting dye-conjugated knottins were
purified by RP-HPLC (Fig. S3C). Masses were confirmed by
MALDI-TOF mass spectrometry (Fig. S3B). AF680-labeled
c(RGDfK) and c(RGDyK) were prepared in a similar manner.
AF680-labeled compounds were lyophilized and resuspended in
PBS, and concentrations were determined using UV-Vis spectros-
copy, measuring dye absorption at 679 nm
(e= 184,000 cm21M21). Alternatively, AF680-labeled knottins
were purified by extensive buffer exchange with PBS using a
centrifugal filter unit with a 3 kDa molecular weight cutoff
(Amicon). In vivo imaging results were consistent between knottins
purified through these two methods. AF680-labeled compounds,
at a concentration of 15 mM in PBS, were passed through a 0.22
mm filter for animal experiments.
Cell binding assays
Competition binding assays were performed on K562 leukemia
cells transfected to express high levels of avb3 integrins [50].
Varying concentrations of AgRP 7C and AgTx variants were
incubated with 56104 K562-avb3 cells in IBB for 4 hr at 4 uC,
along with a constant concentration (0.5 nM) of recombinantly
expressed FLAG-AgRP 7A knottin as a competitor. FLAG-AgRP
7A binds with high affinity to avb3 integrin and contains an N-
terminal epitope tag (DYKDDDDK), allowing cell surface binding
to be detecting using an anti-FLAG antibody [27]. Care was taken
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to allow adequate time for equilibrium binding and to avoid ligand
depleting conditions. After incubation with knottins, cells were
washed with BPBS and resuspended with a 1:100 dilution of R-
PE-conjugated anti-FLAG antibody (Prozyme) for 30 min on ice.
Cells were washed with BPBS and analyzed by flow cytometry on
a FACSCalibur instrument (BD Biosciences), and data was
quantified using FlowJo software (TreeStar). IC50 values were
determined by nonlinear regression analysis using KaleidaGraph
(Synergy Software). Similar competition binding assays were
performed on U87MG glioblastoma cells, which express high
levels of avb3 integrin receptors [70]. EETI 2.5F, AgRP 7C, AgTx
7C DR21, or EETI RDG, unlabeled or site-specifically labeled
with one molecule of AF680 dye, were used for binding
experiments. Varying concentrations of knottins were incubated
with 56104 U87MG cells in IBB for 4 hr at 4 uC with a constant
concentration (5 nM) of FLAG-AgRP 7A as a competitor. Cell
washes, secondary antibody incubation, and data collection and
analysis were performed as for the K562-avb3 binding assays. IC50
values are reported as the mean and standard deviation of at least
three separate experiments.
Mouse handling and generation of tumor xenograft
models
Animal procedures were carried out on 4-week old female nude
mice (Charles River Laboratory). 56106 U87MG cells, suspended
in 50 ml PBS along with 50 ml of Matrigel Basement Membrane
Matrix (BD Biosciences, cat# 354234), were injected subcutane-
ously into the left shoulder of mice to generate human tumor
xenografts. Mice were imaged when tumors reached 5–10 mm in
diameter.
In vivo and ex vivo optical imaging
Mice bearing U87MG tumor xenografts were anesthetized with
isofluorane and injected via tail vein with 1.5 nmol AF680-labeled
knottins, c(RGDfK), or c(RGDyK) in 100 ml of PBS. Whole-body
in vivo fluorescence imaging was performed at the indicated times
after probe injection using an IVIS 200 system (Caliper Life
Sciences). The near-infrared fluorophore AF680 was excited at
615–665 nm and emission was analyzed at 695–770 nm. Back-
ground autofluorescence emission signal was also collected by
exciting at 580–610 nm and analyzing at 695–770 nm. In each
imaging set, a mouse injected with PBS alone (no knottin) was
included to allow measurement of background signals for data
processing. For ex vivo imaging, mice were sacrificed, and organs
were excised and imaged using the same excitation and emission
wavelengths as for in vivo imaging. Excised organs were weighed
to determine the total fluorescent signal flux/gram of tissue.
Imaging quantitation
All optical imaging quantification was performed using Living
Image software (Caliper Life Sciences). In vivo signal was calculated
as [Emission615–665 nm Excitation]–k*[Emission580–610 nm Excitation],
where the constant k was determined such that a background
region of interest (ROI) would have no signal. This background
ROI was drawn around the tumor of the control mouse in each
experiment that received a PBS injection with no knottin. Contrast
was calculated as total radiant efficiency (units of [photons/sec/
cm2/steradian]/[mW/cm2]) for tumor tissue, divided by total
radiant efficiency for an ROI on normal flank tissue on the same
mouse. For ex vivo quantification, total radiant efficiency was
measured for the entire organ, and normalized by the mass of the
organ to determine flux/g of tissue. Two-tailed Student’s t-tests
were used to evaluate and assign statistical significance between data
sets.
Supporting Information
Figure S1 Enzymatic digestion and tandem mass spec-
trometry analysis of folded AgTx 7C reveals an arginine
deletion at position 21. The modified AgTx 7C knottin
(observed mass = 4040 Da) was reduced with dithiothreitol and
alkylated with iodoacetamide. (A) Comparison of MALDI-TOF-
MS of a chymotryptic digest to in silico chymotrypsin digestion
using ExPASy PeptideMass revealed that the mass discrepancy is
located in the sequence GGTPCCRGRPCRCY (position 13–26).
(B) Comparison of tryptic digest to a Mascot search revealed that
Arg19 is present and Arg24 is likely present due to the existence of
fragment 25–34, indicating cleavage by trypsin after residue 24.
This data suggests that the missing Arg is located at residue 21. (C)
MS/MS analysis of the 1600 Da chymotryptic peptide further
supports the sequence GGTPCCRG_PCRCY, with Arg21 as the
most likely deletion, by the observation of y3, y5, y6, y7, and y8
ions.
(TIF)
Figure S2 Modifications to the AgTx scaffold promote in
vitro folding of integrin-binding variants. Analytical-scale
RP-HPLC traces of linear, crude peptide (left), folding reaction
(center), and purified, folded peptide (right) for AgTx 7C variants.
Yield of purified, folded AgTx 7C was too low for further analysis.
AgTx 7C P22G R24I and AgTx 7C DR21 P22G R24I were
efficiently separated from misfolded isomers when folded from
purified, linear precursor peptide, but not when folded from
unpurified, crude peptide under the conditions tested. Thus, for
these variants, crude linear peptide was first purified by
preparatory-scale RP-HPLC using a Vydac C18 column before
folding. In contrast, purification of the AgTx 7C linear precursor
prior to folding still resulted in very low folding efficiency. (B)
Masses of folded, purified knottins were determined by ESI-MS or
MALDI-TOF-MS.
(TIF)
Figure S3 AF680 conjugation and characterization. (A)
The near infrared dye AF680 was site-specifically conjugated to
knottins at their N-terminal amino group using succinimidyl ester
chemistry. (B) Folded, purified knottins and AF680-labeled
knottins were analyzed by mass spectrometry. Expected error in
these measurements is 0.1%. (C) Analysis of purified AF680-
labeled knottins by analytical-scale RP-HPLC. Purity was
determined to be greater than 95%. Blue traces: absorbance at
220 nm by amide bonds, red traces: absorbance at 675 nm by
AF680 fluorophore.
(TIF)
Figure S4 Non-invasive in vivo imaging with AF680-
labeled cyclic RGD peptidomimetics. (A) Mice bearing
U87MG tumor xenografts were injected with 1.5 nmol AF680-
c(RGDfK) or AF680-c(RGDyK), which exhibited high tumor
uptake but slow clearance from non-target tissues. Tumors (white
arrow) and kidneys (K) are indicated. (B) Maximum tumor-to-
normal tissue contrast ratios of 3.260.5 and 2.860.3 were
measured for AF680-c(RGDfK) and AF680-c(RGDyK), respec-
tively. Error bars represent 6 SE, n = 3.
(TIF)
Text S1 Supplemental materials and methods.
(DOCX)
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